Ticlopidine
Active ingredient: Ticlopidine Hydrochloride
In short: Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dys
What is Ticlopidine used for?
Ticlopidine Hydrochloride Tablets USP are indicated:
to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia , ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.
BOXED WARNING
WARNINGS
as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation .
CLINICAL TRIALS
âš Boxed warning (FDA's strongest warning)
Ticlopidine can cause life-threatening hematological adverse reactions, including neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis
Among 2048 patients in clinical trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than 1200 neutrophils/mm ), and the neutrophil count was below 450/mm in 17 of these patients (0.8% of the total population).
3
3
TTP
One case of thrombotic thrombocytopenic purpura was reported during clinical trials in stroke patients. Based on postmarketing data, US physicians reported about 100 cases between 1992 and 1997. Based on an estimated patient exposure of 2 million to 4 million, and assuming an event reporting rate of 10% (the true rate is not known), the incidence of ticlopidine-associated TTP may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia
Aplastic anemia was not seen during clinical trials in stroke patients, but US physicians reported about 50 cases between 1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million, and assuming an event reporting rate of 10% (the true rate is not known), the incidence of ticlopidine-associated aplastic anemia may be as high as one case in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status
Severe hematological adverse reactions may occur within a few days of the start of therapy. The incidence of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately 4 to 6 weeks. …
Ticlopidine dosage
The recommended dose of ticlopidine hydrochloride is 250 mg bid taken with food. Other doses have not been studied in controlled trials for these indications.
The recommended dose of ticlopidine hydrochloride is 250 mg bid taken with food together with antiplatelet doses of aspirin for up to 30 days of therapy following successful stent implantation.
Warnings & precautions
Do not take this medicine if: The use of ticlopidine is contraindicated in the following conditions:
Hypersensitivity to the drug
Presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either TTP or aplastic anemia
Presence of a hemostatic disorder or active pathological bleeding (such as bleeding peptic ulcer or intracranial bleeding)
Patients with severe liver impairment
Ticlopidine should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or pathological conditions. If it is desired to eliminate the antiplatelet effects of ticlopidine prior to elective surgery, the drug should be discontinued 10 to 14 days prior to surgery. Several controlled clinical studies have found increased surgical blood loss in patients undergoing surgery during treatment with ticlopidine. In TASS and CATS it was recommended that patients have ticlopidine discontinued prior to elective surgery. Several hundred patients underwent surgery during the trials, and no excessive surgical bleeding was reported.
Prolonged bleeding time is normalized within 2 hours after administration of 20 mg methylprednisolone IV. Platelet transfusions may also be used to reverse the effect of ticlopidine on bleeding. Because platelet transfusions may accelerate thrombosis in patients with TTP on ticlopidine, they should, if possible, be avoided.
Ticlopidine prolongs template bleeding time. The drug should be used with caution in patients who have lesions with a propensity to bleed (such as ulcers). Drugs that might induce such lesions should be used with caution in patients on ticlopidine .
CONTRAINDICATIONS
Since ticlopidine is metabolized by the liver, dosing of ticlopidine or other drugs metabolized in the liver may require adjustment upon starting or stopping concomitant therapy. …
Ticlopidine side effects
Adverse reactions in stroke patients were relatively frequent with over 50% of patients reporting at least one. Most (30% to 40%) involved the gastrointestinal tract. Most adverse effects are mild, but 21% of patients discontinued therapy because of an adverse event, principally diarrhea, rash, nausea, vomiting, GI pain and neutropenia. Most adverse effects occur early in the course of treatment, but a new onset of adverse effects can occur after several months.
The incidence rates of adverse events listed in the following table were derived from multicenter, controlled clinical trials in stroke patients described above comparing ticlopidine, placebo and aspirin over study periods of up to 5.8 years. Adverse events considered by the investigator to be probably drug-related that occurred in at least 1% of patients treated with ticlopidine are shown in the following table:
Event | Ticlopidine
(n = 2048)
Incidence | Aspirin
(n = 1527)
Incidence | Placebo
(n = 536)
Incidence
Any Events | 60.0 (20.9) | 53.2 (14.5) | 34.3 (6.1)
Diarrhea | 12.5 (6.3) | 5.2 (1.8) | 4.5 (1.7)
Nausea | 7.0 (2.6) | 6.2 (1.9) | 1.7 (0.9)
Dyspepsia | 7.0 (1.1) | 9.0 (2.0) | 0.9 (0.2)
Rash | 5.1 (3.4) | 1.5 (0.8) | 0.6 (0.9)
GI Pain | 3.7 (1.9) | 5.6 (2.7) | 1.3 (0.4)
Neutropenia | 2.4 (1.3) | 0.8 (0.1) | 1.1 (0.4)
Purpura | 2.2 (0.2) | 1.6 (0.1) | 0.0 (0.0)
Vomiting | 1.9 (1.4) | 1.4 (0.9) | 0.9 (0.4)
Flatulence | 1.5 (0.1) | 1.4 (0.3) | 0.0 (0.0)
Pruritus | 1.3 (0.8) | 0.3 (0.1) | 0.0 (0.0)
Dizziness | …
About this medicine
Ticlopidine hydrochloride is a platelet aggregation inhibitor Chemically it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride. The structural formula is:
.
C H ClNS •HCl M.W. 300.25
14
14
Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol, is sparingly soluble in methylene chloride and ethanol, slightly soluble in acetone and insoluble in a buffer solution of pH 6.3.
Each tablet, for oral administration, contains 250 mg of ticlopidine hydrochloride. In addition, each tablet also contains the following inactive ingredients: butylated hydroxyanisole, corn starch, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, stearic acid, and titanium dioxide.
How it works: When taken orally, ticlopidine hydrochloride causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 77d619f8-05a3-408a-a6f8-1511694b6a24. Read the full official label on DailyMed.